Holen Sie sich die Stockscreener-App
0.8299
5.62%
-0.0494
Handel nachbörslich:
.84
0.0101
+1.22%
Schlusskurs vom Vortag:
$0.8793
Offen:
$0.8977
24-Stunden-Volumen:
285.23K
Relative Volume:
0.12
Marktkapitalisierung:
$2.01M
Einnahmen:
$7.06M
Nettoeinkommen (Verlust:
$-21.17M
KGV:
-0.0348
EPS:
-23.879
Netto-Cashflow:
$-28.95M
1W Leistung:
-17.01%
1M Leistung:
-47.81%
6M Leistung:
+18.54%
1J Leistung:
-49.40%
1-Tages-Spanne:
$0.8096
$0.9598
1-Wochen-Bereich:
$0.8096
$1.07
52-Wochen-Spanne:
$0.1806
$6.74
Curis Inc Stock (CRIS) Company Profile
Firmenname
Curis Inc
Sektor
Branche
Telefon
617-503-6500
Adresse
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
0.8299 | 2.01M | 7.06M | -21.17M | -28.95M | -23.88 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-11-17 | Eingeleitet | Truist | Buy |
| 2022-04-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2020-07-29 | Eingeleitet | Laidlaw | Buy |
| 2020-07-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-08-11 | Eingeleitet | FBR Capital | Outperform |
| 2015-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-21 | Bestätigt | ROTH Capital | Buy |
| 2014-05-09 | Bestätigt | Oppenheimer | Outperform |
| 2013-10-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2013-09-30 | Eingeleitet | Chardan Capital Markets | Buy |
| 2012-11-14 | Eingeleitet | Stifel Nicolaus | Hold |
| 2012-01-31 | Bestätigt | Brean Murray | Buy |
| 2012-01-31 | Bestätigt | Summer Street Research | Buy |
| 2011-12-09 | Eingeleitet | Oppenheimer | Outperform |
| 2011-10-06 | Eingeleitet | Summer Street Research | Buy |
| 2011-09-22 | Eingeleitet | MLV Capital | Buy |
| 2011-03-21 | Bestätigt | Brean Murray | Buy |
| 2010-02-26 | Bestätigt | Roth Capital | Buy |
| 2010-01-07 | Eingeleitet | Roth Capital | Buy |
Alle ansehen
Curis Inc Aktie (CRIS) Neueste Nachrichten
Curis Stock Price Forecast. Should You Buy CRIS? - StockInvest.us
CRIS Stock Price, Quote & Chart - ChartMill
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer - GlobeNewswire Inc.
Curis Inc. (CRIS) Slides 8.26% to $1.00 as Shares Press Key SupportSize Factor - dars.gov.et
Curis Inc. stock holds steady as investors weigh recent clinical and financial signals - AD HOC NEWS
Curis Inc (CRIS) Stock Price Target & Forecast - TradingKey
Curis Inc. (NASDAQ:CRIS) - intelligentinvestor.com.au
Curis Inc. (CRIS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Curis Inc. (CRIS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
CRIS Q2 2026 Earnings: 49.73% EPS Beat Fails to Prevent 2.82% Stock DeclineEarnings Quality Analysis - vinanet.vn
CRIS Q2 2026 Earnings: Narrower-Than-Expected Loss Produces 49.7% EPS Beat, Yet Shares Drift LowerCore Business Growth - dars.gov.et
Curis stock context as market data stays elusive - ad-hoc-news.de
Curis (CRIS) Earnings Snapshot: EPS Falls Short of Its Estimate at the Close; Market Move: The Stock Loses 1.86% for the Current SessionEarnings Miss Alert - vinanet.vn
Curis (CRIS) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark for This Review; Stock Move: The Stock Gains 1.18% in the Latest SessionAnnual Financial Report - dars.gov.et
Curis (CRIS) Results Versus Estimates: EPS Falls Short of Its Estimate in Latest Trading; Trading Move: Shares Finish 5.56% Down in the Current UpdateEarnings Deceleration Risk - vinanet.vn
Curis (CRIS) Price Update: Slides 5.56% to $1.70; Boundary Check: the $1.61 to $1.78 Range Remains in Focus for the Current SessionDark Pool Volume - vinanet.vn
CRIS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $43 - GuruFocus
Curis announces pricing of $5.6M public offering - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Curis Inc.’s 1-for-20 Reverse Split Raises Liquidity Concerns and Odd-Lot Trading Risks - TipRanks
CRIS Q1 2026 Earnings: EPS Misses by 206.37% as Stock Slides 3.74%Profit Growth Outlook - vinanet.vn
Curis Inc. (CRIS) Slips 3.74% to $1.80: Key Support and Resistance Levels in FocusFear Greed Extreme - vinanet.vn
Curis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Curis: Q2 Earnings Snapshot - AOL.com
CURIS INC 10-Q Summary: Revenue $0 Net income ($8.58M), EPS ($4.02) — 10-Q Summary - TradingView
Curis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Curis Prices $5.6 Million Public Offering With Healthcare-Focused Institutional Investors - marketscreener.com
CRIS Looks 91.8% Undervalued on GF Value™ Amid Unprofitability C - GuruFocus
Curis prices $5.6 million public offering at $1.50 per share By Investing.com - Investing.com Canada
Curis prices $5.6 million public offering at $1.50 per share - Investing.com
Curis, Inc. Announces Pricing of $5.6 Million Public Offering - PR Newswire
CURIS INC SEC Filing (Aug 13, 2026) - Stock Titan
IPO Databook: Curis (CRIS US)Aug 2026 - smartkarma.com
Curis Inc (CRIS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Curis (CRIS) seeks cash via best-efforts stock and warrant offering amid going-concern risk - Stock Titan
Curis Inc (CRIS) Stock News Today - TradingKey
Curis Inc expected to post a loss of $7.84 a shareEarnings Preview - TradingView
Curis, Inc. (CRIS) stock price, news, quote and history - au.finance.yahoo.com
Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework - finance.yahoo.com
Primer: Curis Inc (CRIS US)Aug 2026 - Smartkarma
CRIS Q1 2026 Earnings: Deep EPS Miss Highlights Clinical-Stage HeadwindsEPS Guidance Update - dars.gov.et
CRIS Q1 2026 Earnings: Severe EPS Miss at -25 vs. -8.16 Estimate Signals Deepening Clinical-Stage Losses - vinanet.vn
Curis Inc expected to post a loss of $7.47 a shareEarnings Preview - TradingView
Curis Regains Nasdaq Compliance, Faces One-Year Monitoring - TipRanks
Curis Doses First Five Patients in TakeAim CLL Study - PR Newswire
JonesTrading Maintains Curis(CRIS.US) With Buy Rating, Cuts Target Price to $20 - moomoo.com
CRIS|Curis Inc|Price:1.350|Chg%:-0.020 - TradingKey
Curis Inc. (CRIS) Gains 3.11% as Stock Tests Key Resistance Near $5.23Backspread Trade - vinanet.vn
Curis Inc (CRIS) Institutional Confidence - TradingKey
Curis Inc (CRIS) Cash Flow - TradingKey
Curis Inc (CRIS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Finanzdaten der Curis Inc-Aktie (CRIS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):